The WHO urgently approves the Novavax Covid-19 vaccine

The World Health Organization (WHO) approved this Tuesday the Covid-19 vaccine of the American company Novavax, based on a more classical and different technology from the drugs already widely used in the European Union.

The European Medicines Agency (EMA) had already authorized the marketing of this immunizer on Monday, Nuvaxovid.

In a statement, the WHO indicated that it is the tenth emergency homologated anticovid vaccine.

Joins vaccines Covaxin del indio Bharat Biontech, Covovax produced by the Serum Institute of India under license from the American Novovax; Pfizer/BioNTech; Modern; AstraZeneca (WHO counts two vaccines of AstraZeneca, one of them made in India), Johnson & Johnson, Sinopharm Y Sinovac.

All of these drugs seek to make the body’s immune system attack the coronavirus, but in different ways.

The so-called protein subunit technology of Novavax has been tested and used for decades to combat diseases such as hepatitis B and the tosferina. It also has the advantage of not requiring storage at very low temperatures, like other immunizers.

Vaccines Pfizer/BioNTech Y Modern, which have dominated the global response to Covid-19, use the pioneering technology of the Messenger RNA.